An interventional study of Superabsorbent dressing application in Venous Leg Ulcer, sponsored by BSN Medical GmbH. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-31.
Sponsored by BSN Medical GmbH · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Varicose Ulcer with a site in United Kingdom — 3 open to participants now, 6 under way, 1 of them phase 3. Varicose Ulcer · United Kingdom.
Among the 38 studies in Varicose Ulcer with a site in United Kingdom, this one is the 10th largest by planned enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2024, is one of 25 with no phase, and was the 34th registered.
371 studies on the registry are indexed under Varicose Ulcer; 75 are open to participants now.
Browse Varicose Ulcer studies →3 of the 38 studies in Varicose Ulcer with a site in United Kingdom are open now. Recruiting first, the newest first:
ConvaTec Inc. · Sites in United Kingdom, Chile
Ages 18+
King's College London · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 50 Varicose Ulcer studies recruiting now, 40 (80%) set no upper age limit and 5 (10%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 152 is above the median of 60 across 310 interventional studies indexed under Varicose Ulcer.
Median enrollment 80 across the 32 interventional studies, 56 across the 6 observational. Of the 32 that completed or were terminated, 13 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 38 have an industry lead sponsor. The 10 most frequent:
BSN Medical GmbH is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
BSN Medical GmbH has 1 study filed under Varicose Ulcer — fewer than ten, so there is no comparison to draw.
2 of the studies in Varicose Ulcer with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06489028Phase 3RHEACELL GmbH & Co. KGAllogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III) | 2027-04 |
| NCT05007301Firstkind LtdGeko™ Cross Therapy Registry - Wound | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 38 studies in Varicose Ulcer with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The fluid handling capacity of superabsorbent dressings varies depending on the design and construction. The use of effective advanced wound dressings is a promising strategy to achieve adequate absorption of wound exudate and malodour promoting wound healing. The aim of the current study is to determine whether there is a difference in the clinical performance of exudate absorption with two commonly used CE-marked superabsorbent dressings when used on VLUs in routine wound care.
As primary objective the dressing´s absorption performance and its ability to prevent skin maceration and leakage of the wound dressing will be investigated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Within this arm the Cutimed Sorbion (Cutimed® Sorbion® Sachet/Sana/Border) products will be used for exudate managment.
Device: Superabsorbent dressing application
Within this arm the comperator products Zetuvit® Plus/(RespoSorb® Super), Zetuvit® Plus Silicone/(RespoSorb® Silicone) and Zetuvit® Plus Silicone Border/(RespoSorb® Silicone Border) will be used for exudate management.
Device: Superabsorbent dressing application
Cutimed Sorbion or Zetuvit plus (RespoSorb) application to maintain wound exudate
Exudate management performance
Capability to main exudate uptake and retention as well as leakage prevention
Time frame: up to 30 days
Dressing change frequency
Number of required intermediate dressing changes between study visits and assessement fo reasons for
Time frame: up to 30 days
Moisture-associated skin damages
Occurrence of moisture-associated skin damages
Time frame: up to 30 days
Occurrence clinical relevant peri-wound skin changes
Effect of product use on peri-wound skin such as reddening, swelling, clinical relevant skin detoriations
Time frame: up to 30 days
Changes in wound tissue and general wound pain
Effect of product use on the wound considering wound tissue and slough on the wound as well as the general wound pain assessed using a 11 visual analogue scale from 0-10 (0= not pain, 10=most imaginable pain for the participant)
Time frame: up to 30 days
Need for debridement after product removal
Evaluation of the soft debridement effect of Cutimed Sorbion products during dressing removal: is the soft debrimdent supporting wound cleansing and eases addtional wound debridement
Time frame: up to 30 days
Patient satisfaction with treatment and product
Patient´s impressions about treatment and felt protection for leakage when using the product and assessment of individually felt wearing comfort
Time frame: final study visit
HCP satisfaction with treatment and product
HCP´s satisfaction with treatment and product performance to manage wound exudate, check if treatment need have been met be the product
Time frame: final study visit
Changes in quality of life using the "Wound-QoL 14" (short questionnaire measuring quality of life in patients with chronic wounds based on three established disease-specific instruments)
Fourteen items are scored using a Likert-type scale as either 'not at all', 'a little', 'moderately', 'quite a lot' or 'very much'. Item data are calculated building a global score and the 3 subscores "Body", "Psyche/Well-being" and the "Everyday life". In increase in quality of life is indicated by decreasing sub- and/or global score.
Time frame: day 0 and day 30
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Nov 2025, 15 months after the start.
Of 67 industry-sponsored interventional studies with no phase under Varicose Ulcer, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 15 months is below that.
Counting every sponsor, half of 134 studies reached it within 28 months; a quarter within 13 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
BSN Medical GmbH